Bio-Rad Laboratories Management
Management criteria checks 4/4
Bio-Rad Laboratories' CEO is Norman Schwartz, appointed in Jan 2003, has a tenure of 21.83 years. total yearly compensation is $7.46M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 4.34% of the company’s shares, worth $404.78M. The average tenure of the management team and the board of directors is 3.4 years and 7.6 years respectively.
Key information
Norman Schwartz
Chief executive officer
US$7.5m
Total compensation
| CEO salary percentage | 13.9% |
| CEO tenure | 21.8yrs |
| CEO ownership | 4.3% |
| Management average tenure | 3.4yrs |
| Board average tenure | 7.6yrs |
Recent management updates
Recent updates
Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Nov 25Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?
Nov 25
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$779m |
| Jun 30 2024 | n/a | n/a | -US$1b |
| Mar 31 2024 | n/a | n/a | -US$322m |
| Dec 31 2023 | US$7m | US$1m | -US$637m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$428m |
| Mar 31 2023 | n/a | n/a | -US$191m |
| Dec 31 2022 | US$8m | US$1m | -US$4b |
| Sep 30 2022 | n/a | n/a | -US$6b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$9m | US$988k | US$4b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$8m | US$987k | US$4b |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$950k | US$2b |
| Sep 30 2019 | n/a | n/a | US$377m |
| Jun 30 2019 | n/a | n/a | US$905m |
| Mar 31 2019 | n/a | n/a | US$574m |
| Dec 31 2018 | US$8m | US$942k | US$366m |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$1b |
| Mar 31 2018 | n/a | n/a | US$767m |
| Dec 31 2017 | US$5m | US$922k | US$122m |
Compensation vs Market: Norman's total compensation ($USD7.46M) is about average for companies of similar size in the US market ($USD7.74M).
Compensation vs Earnings: Norman's compensation has been consistent with company performance over the past year.
CEO
Norman Schwartz (74 yo)
21.8yrs
Tenure
US$7,463,878
Compensation
Mr. Norman D. Schwartz was Principal Financial Officer of Bio-Rad Laboratories, Inc. since February 9, 2024 until April 15, 2024 and served as its Interim CFO until February 9, 2024. He serves as an Indepe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 21.8yrs | US$7.46m | 4.34% $ 404.8m | |
| President & COO | less than a year | no data | no data | |
| Executive VP & CFO | less than a year | no data | no data | |
| Senior Director | 3.4yrs | no data | 0.00020% $ 18.7k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior Vice President and Chief Compliance & Privacy Officer | no data | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Executive Vice President of Global Human Resources | 10.6yrs | no data | 0.066% $ 6.2m | |
| Executive Vice President of Global Commercial Operations | 9.9yrs | US$2.68m | 0.029% $ 2.7m | |
| Senior Vice President of Global Commercial Operations - Asia Pacific | no data | no data | no data | |
| Executive VP & President of Life Science Group | no data | no data | 0.00053% $ 49.5k | |
| Senior Vice President of Global Commercial Operations of Europe | no data | no data | no data |
3.4yrs
Average Tenure
60yo
Average Age
Experienced Management: BIO's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 29.8yrs | US$7.46m | 4.34% $ 404.8m | |
| Lead Independent Director | 7.6yrs | US$199.25k | 0.0018% $ 167.0k | |
| Director Emeritus | 2.6yrs | US$40.18k | 11.46% $ 1.1b | |
| Independent Director | 7.6yrs | US$190.00k | no data | |
| Independent Director | 7.6yrs | US$178.75k | no data | |
| Independent Director | 7.6yrs | US$195.00k | no data | |
| Director | 2.6yrs | no data | 0.019% $ 1.7m |
7.6yrs
Average Tenure
66yo
Average Age
Experienced Board: BIO's board of directors are considered experienced (7.6 years average tenure).